RARE: Leadership change

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As reported below, at its Annual Meeting of Stockholders (the “ Annual Meeting ”) on May 14, 2026, the stockholders of Ultragenyx Pharmaceutical Inc. (“ Ultragenyx ” or the “ Company ”) approved the Third Amended and Restated 2023 Incentive Plan (the “ Third A&R 2023 Plan ”). The Third A&R 2023 Plan is described in more detail in Ultragenyx’s 2026 Proxy Statement (“ Proxy Statement ”), filed with the Securities and Exchange Commission (the “ SEC ”) on March 27, 2026. The foregoing description and the description incorporated by reference from the Proxy Statement are qualified in their entirety by reference to the Third A&R 2023 Plan, a copy of which is filed as Exhibit 10.1 and is incorporated herein by reference. Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2026, the Company held its Annual Meeting. As of the record date of March 23, 2026, 98,317,221 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A total of 84,786,388 shares of the Company’s common stock were represented in person or by proxy at the Annual Meeting. Proposal No. 1 – Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows: Class I Director Nominees Votes For Votes Withheld Broker Non-Votes Emil D. Kakkis, M.D., Ph.D. 72,517,613 1,056,885 11,211,890 Shehnaaz Suliman, M.D. 65,801,638 7,772,860 11,211,890 Daniel G. Welch 66,301,426 7,2